Drug Development RFP
Funds IND-enabling studies and early clinical trials for innovative drugs and devices targeting Alzheimer's disease and related dementias, emphasizing diverse biological mechanisms and rigorous, biomarker-based research.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026 (Letter of Intent)
Funding Amounts: Up to $5,000,000 per project; multi-year awards; only direct costs allowed.
Summary: Supports IND-enabling studies and early-phase clinical trials for novel, repurposed, or repositioned therapies targeting Alzheimer's disease and related dementias.
Key Information: Funding is structured as mission-related investments with milestone-based payments.
Description
This opportunity funds investigational new drug (IND)-enabling studies and early-phase clinical trials for promising pharmacological interventions and devices addressing Alzheimer’s disease and related dementias. The program emphasizes diverse drug mechanisms and modes of action related to the biology of aging, prioritizing novel, repurposed, and repositioned drugs, as well as natural products and devices. High-priority areas include epigenetics, inflammation, mitochondrial/metabolic function, neuroprotection, proteostasis, synaptic activity, vascular function, and other aging-related pathways. Proposals must provide strong scientific rationale, robust preclinical and clinical data, and rigorous study design with biomarker-based assessments.
